SlideShare ist ein Scribd-Unternehmen logo
1 von 5
Downloaden Sie, um offline zu lesen
Issue 12 | June 2010                      www.plg-uk.com




Business Development
& Licensing Journal
For the Pharmaceutical Licensing Groups

Follow-on biologics
Co-marketing:
a successful model
Trends in dealmaking
Finding new
products to license



                       ADVERT
Plan B: when
negotiations fail
Finding new products
to license
There are many ways to get advice on best practice for product selection,
deal structure, contract negotiation and partnerships, but little on where
to find the products to license and partners to do business with in the
first place. Fortunately, technology can help.
By Asa Cox, founder, Generic Licensing




                                                    B
                                                             ig pharma and generics used to              made to feel more substantial by the multiple
                                                             do battle at patent expiry; now we          automated emails churning out the
                                                             see the companies playing in each           same story.
                                                    other’s sandpits more often. Big pharma is              Why is this? Is it because too few of the
                                                    jumping into ‘established products’ as a way         products available are attractive? Is it because
                                                    of utilising brand equity and oversized sales        there is not enough money to acquire new
                                                    forces. Generics are adding value to older           products? Is it that deals are frustrated due
                                                    products through formulation development             to lack of capacity or capability? Or is it that
                                                    and need marketing to add a barrier to entry         everyone is competing with each other to do
                                                    for copycat products.                                deals with the same companies for the same
                                                       Historically mergers and acquisitions             products?
                                                    have been a key means of growth for the                 Our hypothesis is that there are many
                                                    dominant players on both sides; product              stones left unturned, and that as emerging
                                                    licensing deals have been the major force in         markets and technologies begin to dominate
                                                    more recent years and it is likely to remain         other industries, so pharma needs to use
                                                    that way for as long as shareholders want to         different ways to exploit the potential of
                                                    see results and not just potential.                  both.
                                                       Of course with licensing, profit margins
                                                    are reduced, as is research and development          The challenges
                                                    kudos (a factor that now seems to have               There are challenges to overcome. Common
                                                    been rightly exchanged for a closer focus            issues include the fact that engaging
                                                    on commercial value). Time to market, risk           potential partner organisations in emerging
                                                    and tactical fit are good enough reasons to          markets can be hard work, with differences
                                                    make such concessions. For those without             in language, business culture, commercial
                                                    a pipeline to perk up sluggish share prices it       experience and ethics. In addition, when
  About the author                                  is a matter of survival. Licensing is not to be      it comes to new technologies and partner
  Asa Cox is founder of genericlicensing.com,       viewed just as ventilator though, more like a        channels some will work; some won’t. You
  the pharma industry’s first searchable internet   Statin or an Aspirin for those of longer tooth.      need to know what the acceptable risk/
  database of generic products available for                                                             investment for progress or future return is.
  licensing. He is a dedicated web evangelist       Finding potential                                    And breaking the mould can be a lonely
  and online networker. Asa is also a Director of   Given the numbers involved in the                    venture, with unfamiliar situations and
  IPG Pharma, a 13-year-old technical services      combination of human ailments, healthcare            unfamiliar faces. Everyone prefers the
  company based in Berkshire.                       companies and research strands, one would            comfort zone.
  T: +44 (0)845 453 1363                            have thought there would be a torrent of                 As Confucius said: “I know why the path
  E: asa.cox@genericlicensing.com                   licensing news flooding our email inboxes            is not trodden; the clever ones overstep it
                                                    on a daily basis. But it is really just a trickle,   and the stupid ones do not reach it.” For

20 Business Development & Licensing Journal                                                                                          www.plg-uk.com
some companies, the drive for efficiency in     too late and now everyone will be keeping an                To find new
deal-making channels means the business         eye on them.
development teams back into tried and               Some of the larger data houses and                 partners or products
tested sources and techniques. Such             platforms are beginning to realise they are            and to avoid license
companies believe that they already know the
best places to find products and expect that
                                                behind with regard to partnering. Recently
                                                developments have seen the integration
                                                                                                       auctions, it is
highly tuned management systems will drive      of user-specific information with editorial,           important to seek
the licensing teams to be more productive.      combining lead searches with contact lists to          new opportunities
They step over the path.                        create a more dynamic environment. These
   Other companies believe that licensing       innovations are the only way in which such             in uncharted waters.
a new product is easy, and is a matter          conglomerates are going to survive against             Everyone needs
of keeping an eye on the industry press,
attending as many conferences as possible,
                                                the onslaught of free web products.
                                                    There are, however, a few sites that
                                                                                                       differentiation and
working the rolodex and networking. They        proactively seek out new companies                     innovation.
do not reach the path.                          that have products to license and need
   To find new partners or products and         help getting more visibility. These include
to avoid license auctions, it is important to   pharmadeals.com, pharmalicensing.com,
seek new opportunities in uncharted waters.     pharmaprojects.com, sourcegenerics.com
These ideas are not just relevant for big       and farmavita.net. On some of these sites
pharma or generic giants; everyone needs        it is possible to save searches and have new
differentiation and innovation. There are       companies that match criteria sent via email
existing opportunities and future ventures      automatically, so you need only visit once to
that could unearth the new opportunities,       get a stream of potential leads. The internet
including online databases/portals,             is now the first place companies research
virtual partnering forums, internet speed       potential new marketing partners.
networking, niche partnering events and
collaboration platforms.                        Virtual partnering forums
                                                Although there are a few events in the
Online databases/portals                        calendar already, this is going to be an
Companies that offer deal data are nothing      area of massive growth in coming years.
revolutionary; the advent of online news feed   Modelled on real-world conference centres,
aggregation means that press statements are     each has exhibition booths with multimedia
distributed from every angle instantaneously.   displays and live chat (with video and voice if
While such news sites can provide a lead list   desired), keynote speaker presentations and
of active licensing companies, the fact they    networking lounges.
are announcing a deal normally means it’s          Improving broadband connections,               >>

www.plg-uk.com                                                                                                Issue 12 | June 2010 21
To discover unknown companies and
exciting products, one needs to get out of the
zoo and into the jungle. Such exotic terrain
requires a specialist tour guide.




                                    >>   streaming media and browser-based                   20 minutes over 2 hours) and not have to
                                         applications are all making virtual reality         even leave the office?
                                         a much richer and more stimulating                     Webcams, Skype and simple web
                                         environment.                                        interfaces will soon enable licensing teams,
                                             Reduced budgets, increased focus on             brokers and industry associations to host well
                                         carbon footprints and greater time pressures        researched events that have a better than
                                         are all factors which count against the             average return on time invested.
                                         traditional big shows and live partnering
                                         events. This pressure is increased when             Niche partnering events
                                         considering emerging markets with excellent         Bigger isn’t always better. The giant
                                         IT infrastructure and executives that are a         partnering events like Bio, while enabling
                                         little less inclined to travel or blow budgets on   thousands to meet under one roof, is focused
                                         only a few trips a year.                            on volume of attendees and meetings. To
                                             Events already in the calendar                  discover unknown companies and exciting
                                         include bioconferencelive.com,                      products, one needs to get out of the zoo
                                         pharmapartneringlive2010.com,                       and into the jungle. Such exotic terrain
                                         cardiocarelive.com and informex.com/virtual.        requires a specialist tour guide; one with
                                             Some of the larger pharma companies             local knowledge and a connection with the
                                         now have their own partnering web                   environment.
                                         presence; although not well promoted, they             There are already a number of key events
                                         provide a 24/7 opportunity for engagement           on the calendar in high-growth markets,
                                         and information sharing with potential              including innchinc.com/wpcs2010, cphi-sa.
                                         partners. Expect to see many more of these          com, eilat-aeds.com and kenes.com/ipa.
                                         virtual meeting spaces as a cost-effective way      We can expect to see an increased focus on
                                         to attract interest from every corner of the        therapy areas and research and development

    Expect to see                        industry.                                           technologies.

many more virtual                        Internet speed networking                           Collaboration platforms
meeting spaces as a                      Sometimes introductory meetings can take
                                         much longer than necessary or desired and
                                                                                             The future of licensing deals, ie one company
                                                                                             acquiring the rights to another’s intellectual
cost-effective way to                    can be especially unproductive if they are part     property, is a model that will morph as
attract interest from                    of the mandatory requirements of partner            technology and business structures develop.

every corner of the                      events.
                                            What better than to have multiple
                                                                                             In other industries where innovation,
                                                                                             consumer (patient) alignment and long-term
industry.                                meetings in a short space of time (say every        value is a high priority, companies are joining

22 Business Development & Licensing Journal                                                                              www.plg-uk.com
together in collaboration like never before.      networks may not be an effective channel                 Given the global
    Web 2.0 is about integration, open source
and user content creation. Business 2.0 (or
                                                  into the new opportunities. To connect with
                                                  the developers of tomorrow is going to
                                                                                                       spread of future
more like 200.0) will mimic this trend, as        require a more high-tech approach.                   intellectual workers,
corporations seek to compete with the next           The internet is making the world and              personal contacts
Facebook/Spotify/Apple of their space and         every industry smaller; companies from
start-ups discover game-changing ways to          every corner of the globe should be seeking          and networks may
work together, disrupting the establishment.      ways to do business with each other before           not be an effective
How will the pharma industry look in 10
years’ time? How will that affect licensing?
                                                  someone else does.
                                                     If, as forecast, the BRIC countries are going
                                                                                                       channel into the new
    Pharma is founded on research and             to dominate the future economy, are you              opportunities.
development (more development in                  already connected in those markets? If not,
generics) and finding better ways to bring        why not? If, as forecast, technology is going
more products to market. One way that             to change the face of all industries, including
the corporate model could be challenged           pharma, are you investigating how you can
is through the creation of loose networks         get ahead of the game? If not, why not?
of specialist teams and individuals for           Tomorrow’s deals are not going to wait for
specific projects, or to harness a unique joint   you.
capability.                                          In the future, the products to license are
    With such experts having access to            not going to be found in the same places
powerful technology infrastructure and            as yesterday or today. The individuals and
a willingness to achieve more through             countries that will create the products of
collaboration, licensing deals may be done        tomorrow will be better integrated with
with individuals or specific business vehicles.   technology and more accessible to those who
                                                  embrace the same.
The future                                           There are already more innovative ways
The future integration and collaboration of       to engage with new partners with new
development bodies could make deal making         products; it just takes a little step out into the
a lot more complex. Such open platforms           unknown, to depart from the old school and
could also mean that options and sponsorship      adopt some new tools.
or other commercial tools could tie up the
best minds before the products reach the
licensing space.
   Given the global spread of future
intellectual workers, personal contacts and

www.plg-uk.com                                                                                                Issue 12 | June 2010 23

Weitere ähnliche Inhalte

Ähnlich wie How to find new products to license (plg journal july 2010)

Maximizing Return On Innovation
Maximizing Return On InnovationMaximizing Return On Innovation
Maximizing Return On InnovationInfosys
 
Stratgic imitation-Road to business growth
Stratgic imitation-Road to business growthStratgic imitation-Road to business growth
Stratgic imitation-Road to business growthBrowne & Mohan
 
How structural collaboration leads to value propositions in the financial sector
How structural collaboration leads to value propositions in the financial sectorHow structural collaboration leads to value propositions in the financial sector
How structural collaboration leads to value propositions in the financial sectorInSites Consulting
 
How structural collaboration leads to value propositions in the financial sector
How structural collaboration leads to value propositions in the financial sectorHow structural collaboration leads to value propositions in the financial sector
How structural collaboration leads to value propositions in the financial sectorTom De Ruyck
 
Triallianceeffect 100510013748-phpapp02
Triallianceeffect 100510013748-phpapp02Triallianceeffect 100510013748-phpapp02
Triallianceeffect 100510013748-phpapp02jorge andres
 
Using Business Development to Grow Your SaaS Startup
Using Business Development to Grow Your SaaS StartupUsing Business Development to Grow Your SaaS Startup
Using Business Development to Grow Your SaaS StartupEmergence Capital Partners
 
Startup Engagement : Best Practices for Large Organizations
Startup Engagement : Best Practices for Large OrganizationsStartup Engagement : Best Practices for Large Organizations
Startup Engagement : Best Practices for Large OrganizationsMohsen Mokhtari
 
The Case for R&D Outsourcing
The Case for R&D OutsourcingThe Case for R&D Outsourcing
The Case for R&D OutsourcingInfosys
 
Seven Ways Traditional Companies Can Succeed with Disruptive Innovation
Seven Ways Traditional Companies Can Succeed with Disruptive InnovationSeven Ways Traditional Companies Can Succeed with Disruptive Innovation
Seven Ways Traditional Companies Can Succeed with Disruptive InnovationCognizant
 
An Insider’s Guide to Acquisitions for the Mid-sized Company - Part 3 of 9
An Insider’s Guide to Acquisitions for the Mid-sized Company - Part 3 of 9An Insider’s Guide to Acquisitions for the Mid-sized Company - Part 3 of 9
An Insider’s Guide to Acquisitions for the Mid-sized Company - Part 3 of 9Brad D. Cherniak
 
Sustainable competitive advantage cs & notes toyota cs
Sustainable competitive advantage cs & notes toyota csSustainable competitive advantage cs & notes toyota cs
Sustainable competitive advantage cs & notes toyota csiipmff2
 
Technology of innovation
Technology of innovationTechnology of innovation
Technology of innovationPivotal CRM
 
Avoiding The “Silver Bullet Syndrome”
Avoiding The “Silver Bullet Syndrome”Avoiding The “Silver Bullet Syndrome”
Avoiding The “Silver Bullet Syndrome”G3 Communications
 
Is your company reaping ecosystem advantages??
Is your company reaping ecosystem advantages??Is your company reaping ecosystem advantages??
Is your company reaping ecosystem advantages??Browne & Mohan
 
Stop Isolating Customer Insights: Five Ways to Design the Customer Into Your ...
Stop Isolating Customer Insights: Five Ways to Design the Customer Into Your ...Stop Isolating Customer Insights: Five Ways to Design the Customer Into Your ...
Stop Isolating Customer Insights: Five Ways to Design the Customer Into Your ...Mohamed Mahdy
 
Strategy fromthe Inside OutBUILDING CAPABILITY-CREATING.docx
Strategy fromthe Inside OutBUILDING CAPABILITY-CREATING.docxStrategy fromthe Inside OutBUILDING CAPABILITY-CREATING.docx
Strategy fromthe Inside OutBUILDING CAPABILITY-CREATING.docxjohniemcm5zt
 

Ähnlich wie How to find new products to license (plg journal july 2010) (20)

Maximizing Return On Innovation
Maximizing Return On InnovationMaximizing Return On Innovation
Maximizing Return On Innovation
 
Stratgic imitation-Road to business growth
Stratgic imitation-Road to business growthStratgic imitation-Road to business growth
Stratgic imitation-Road to business growth
 
How structural collaboration leads to value propositions in the financial sector
How structural collaboration leads to value propositions in the financial sectorHow structural collaboration leads to value propositions in the financial sector
How structural collaboration leads to value propositions in the financial sector
 
How structural collaboration leads to value propositions in the financial sector
How structural collaboration leads to value propositions in the financial sectorHow structural collaboration leads to value propositions in the financial sector
How structural collaboration leads to value propositions in the financial sector
 
Triallianceeffect 100510013748-phpapp02
Triallianceeffect 100510013748-phpapp02Triallianceeffect 100510013748-phpapp02
Triallianceeffect 100510013748-phpapp02
 
Using Business Development to Grow Your SaaS Startup
Using Business Development to Grow Your SaaS StartupUsing Business Development to Grow Your SaaS Startup
Using Business Development to Grow Your SaaS Startup
 
Startup Engagement : Best Practices for Large Organizations
Startup Engagement : Best Practices for Large OrganizationsStartup Engagement : Best Practices for Large Organizations
Startup Engagement : Best Practices for Large Organizations
 
The Case for R&D Outsourcing
The Case for R&D OutsourcingThe Case for R&D Outsourcing
The Case for R&D Outsourcing
 
Sp white paper
Sp white paperSp white paper
Sp white paper
 
Bm 13016
Bm 13016Bm 13016
Bm 13016
 
ACEOsGuide
ACEOsGuideACEOsGuide
ACEOsGuide
 
Seven Ways Traditional Companies Can Succeed with Disruptive Innovation
Seven Ways Traditional Companies Can Succeed with Disruptive InnovationSeven Ways Traditional Companies Can Succeed with Disruptive Innovation
Seven Ways Traditional Companies Can Succeed with Disruptive Innovation
 
An Insider’s Guide to Acquisitions for the Mid-sized Company - Part 3 of 9
An Insider’s Guide to Acquisitions for the Mid-sized Company - Part 3 of 9An Insider’s Guide to Acquisitions for the Mid-sized Company - Part 3 of 9
An Insider’s Guide to Acquisitions for the Mid-sized Company - Part 3 of 9
 
Sustainable competitive advantage cs & notes toyota cs
Sustainable competitive advantage cs & notes toyota csSustainable competitive advantage cs & notes toyota cs
Sustainable competitive advantage cs & notes toyota cs
 
Technology of innovation
Technology of innovationTechnology of innovation
Technology of innovation
 
Advantage By Design
Advantage By DesignAdvantage By Design
Advantage By Design
 
Avoiding The “Silver Bullet Syndrome”
Avoiding The “Silver Bullet Syndrome”Avoiding The “Silver Bullet Syndrome”
Avoiding The “Silver Bullet Syndrome”
 
Is your company reaping ecosystem advantages??
Is your company reaping ecosystem advantages??Is your company reaping ecosystem advantages??
Is your company reaping ecosystem advantages??
 
Stop Isolating Customer Insights: Five Ways to Design the Customer Into Your ...
Stop Isolating Customer Insights: Five Ways to Design the Customer Into Your ...Stop Isolating Customer Insights: Five Ways to Design the Customer Into Your ...
Stop Isolating Customer Insights: Five Ways to Design the Customer Into Your ...
 
Strategy fromthe Inside OutBUILDING CAPABILITY-CREATING.docx
Strategy fromthe Inside OutBUILDING CAPABILITY-CREATING.docxStrategy fromthe Inside OutBUILDING CAPABILITY-CREATING.docx
Strategy fromthe Inside OutBUILDING CAPABILITY-CREATING.docx
 

Mehr von Generic Pharma 2.0

New Pharma Magazine Launch Party in NYC!
New Pharma Magazine Launch Party in NYC! New Pharma Magazine Launch Party in NYC!
New Pharma Magazine Launch Party in NYC! Generic Pharma 2.0
 
GP20 Licensing Pavillion 2012 Coexhibitor Kit
GP20 Licensing Pavillion 2012 Coexhibitor KitGP20 Licensing Pavillion 2012 Coexhibitor Kit
GP20 Licensing Pavillion 2012 Coexhibitor KitGeneric Pharma 2.0
 
BioSimilar Drug Development World
BioSimilar Drug Development WorldBioSimilar Drug Development World
BioSimilar Drug Development WorldGeneric Pharma 2.0
 
New Pharma Magazine Seeking Contributors
New Pharma Magazine Seeking ContributorsNew Pharma Magazine Seeking Contributors
New Pharma Magazine Seeking ContributorsGeneric Pharma 2.0
 
OTC Licensing Product Portfolio
OTC Licensing Product PortfolioOTC Licensing Product Portfolio
OTC Licensing Product PortfolioGeneric Pharma 2.0
 
CPHI 2012! Generic Pharma 2.0 Stand Design
CPHI 2012! Generic Pharma 2.0 Stand DesignCPHI 2012! Generic Pharma 2.0 Stand Design
CPHI 2012! Generic Pharma 2.0 Stand DesignGeneric Pharma 2.0
 
Neogen presentation april_2011_gl
Neogen presentation april_2011_glNeogen presentation april_2011_gl
Neogen presentation april_2011_glGeneric Pharma 2.0
 
Genericlicensing.com - featured companies 2011
Genericlicensing.com - featured companies 2011Genericlicensing.com - featured companies 2011
Genericlicensing.com - featured companies 2011Generic Pharma 2.0
 
2011 Global Generic Product Directory Demo
2011 Global Generic Product Directory Demo2011 Global Generic Product Directory Demo
2011 Global Generic Product Directory DemoGeneric Pharma 2.0
 
Biosimilars - analysing market intelligence (Peter Wittner)
Biosimilars - analysing market intelligence (Peter Wittner)Biosimilars - analysing market intelligence (Peter Wittner)
Biosimilars - analysing market intelligence (Peter Wittner)Generic Pharma 2.0
 

Mehr von Generic Pharma 2.0 (20)

WSGR Alert
WSGR AlertWSGR Alert
WSGR Alert
 
New Pharma Magazine Launch Party in NYC!
New Pharma Magazine Launch Party in NYC! New Pharma Magazine Launch Party in NYC!
New Pharma Magazine Launch Party in NYC!
 
Cheryl investigates
Cheryl investigatesCheryl investigates
Cheryl investigates
 
GP20 Licensing Pavillion 2012 Coexhibitor Kit
GP20 Licensing Pavillion 2012 Coexhibitor KitGP20 Licensing Pavillion 2012 Coexhibitor Kit
GP20 Licensing Pavillion 2012 Coexhibitor Kit
 
BioSimilar Drug Development World
BioSimilar Drug Development WorldBioSimilar Drug Development World
BioSimilar Drug Development World
 
Your Ideal Pfizer
Your Ideal PfizerYour Ideal Pfizer
Your Ideal Pfizer
 
Animal health
Animal healthAnimal health
Animal health
 
Moving @ the Speed of Social
Moving @ the Speed of SocialMoving @ the Speed of Social
Moving @ the Speed of Social
 
New Pharma Magazine Seeking Contributors
New Pharma Magazine Seeking ContributorsNew Pharma Magazine Seeking Contributors
New Pharma Magazine Seeking Contributors
 
OTC Licensing Product Portfolio
OTC Licensing Product PortfolioOTC Licensing Product Portfolio
OTC Licensing Product Portfolio
 
LinkedIn Survey Results
LinkedIn Survey ResultsLinkedIn Survey Results
LinkedIn Survey Results
 
CPHI 2012! Generic Pharma 2.0 Stand Design
CPHI 2012! Generic Pharma 2.0 Stand DesignCPHI 2012! Generic Pharma 2.0 Stand Design
CPHI 2012! Generic Pharma 2.0 Stand Design
 
GL infographics
GL infographicsGL infographics
GL infographics
 
New Pharma Magazine
New Pharma MagazineNew Pharma Magazine
New Pharma Magazine
 
Woerwag RD presentation
Woerwag RD presentationWoerwag RD presentation
Woerwag RD presentation
 
Neogen presentation april_2011_gl
Neogen presentation april_2011_glNeogen presentation april_2011_gl
Neogen presentation april_2011_gl
 
Genericlicensing.com - featured companies 2011
Genericlicensing.com - featured companies 2011Genericlicensing.com - featured companies 2011
Genericlicensing.com - featured companies 2011
 
2011 Global Generic Product Directory Demo
2011 Global Generic Product Directory Demo2011 Global Generic Product Directory Demo
2011 Global Generic Product Directory Demo
 
Heal gel presentation
Heal gel presentationHeal gel presentation
Heal gel presentation
 
Biosimilars - analysing market intelligence (Peter Wittner)
Biosimilars - analysing market intelligence (Peter Wittner)Biosimilars - analysing market intelligence (Peter Wittner)
Biosimilars - analysing market intelligence (Peter Wittner)
 

How to find new products to license (plg journal july 2010)

  • 1. Issue 12 | June 2010 www.plg-uk.com Business Development & Licensing Journal For the Pharmaceutical Licensing Groups Follow-on biologics Co-marketing: a successful model Trends in dealmaking Finding new products to license ADVERT Plan B: when negotiations fail
  • 2. Finding new products to license There are many ways to get advice on best practice for product selection, deal structure, contract negotiation and partnerships, but little on where to find the products to license and partners to do business with in the first place. Fortunately, technology can help. By Asa Cox, founder, Generic Licensing B ig pharma and generics used to made to feel more substantial by the multiple do battle at patent expiry; now we automated emails churning out the see the companies playing in each same story. other’s sandpits more often. Big pharma is Why is this? Is it because too few of the jumping into ‘established products’ as a way products available are attractive? Is it because of utilising brand equity and oversized sales there is not enough money to acquire new forces. Generics are adding value to older products? Is it that deals are frustrated due products through formulation development to lack of capacity or capability? Or is it that and need marketing to add a barrier to entry everyone is competing with each other to do for copycat products. deals with the same companies for the same Historically mergers and acquisitions products? have been a key means of growth for the Our hypothesis is that there are many dominant players on both sides; product stones left unturned, and that as emerging licensing deals have been the major force in markets and technologies begin to dominate more recent years and it is likely to remain other industries, so pharma needs to use that way for as long as shareholders want to different ways to exploit the potential of see results and not just potential. both. Of course with licensing, profit margins are reduced, as is research and development The challenges kudos (a factor that now seems to have There are challenges to overcome. Common been rightly exchanged for a closer focus issues include the fact that engaging on commercial value). Time to market, risk potential partner organisations in emerging and tactical fit are good enough reasons to markets can be hard work, with differences make such concessions. For those without in language, business culture, commercial a pipeline to perk up sluggish share prices it experience and ethics. In addition, when About the author is a matter of survival. Licensing is not to be it comes to new technologies and partner Asa Cox is founder of genericlicensing.com, viewed just as ventilator though, more like a channels some will work; some won’t. You the pharma industry’s first searchable internet Statin or an Aspirin for those of longer tooth. need to know what the acceptable risk/ database of generic products available for investment for progress or future return is. licensing. He is a dedicated web evangelist Finding potential And breaking the mould can be a lonely and online networker. Asa is also a Director of Given the numbers involved in the venture, with unfamiliar situations and IPG Pharma, a 13-year-old technical services combination of human ailments, healthcare unfamiliar faces. Everyone prefers the company based in Berkshire. companies and research strands, one would comfort zone. T: +44 (0)845 453 1363 have thought there would be a torrent of As Confucius said: “I know why the path E: asa.cox@genericlicensing.com licensing news flooding our email inboxes is not trodden; the clever ones overstep it on a daily basis. But it is really just a trickle, and the stupid ones do not reach it.” For 20 Business Development & Licensing Journal www.plg-uk.com
  • 3. some companies, the drive for efficiency in too late and now everyone will be keeping an To find new deal-making channels means the business eye on them. development teams back into tried and Some of the larger data houses and partners or products tested sources and techniques. Such platforms are beginning to realise they are and to avoid license companies believe that they already know the best places to find products and expect that behind with regard to partnering. Recently developments have seen the integration auctions, it is highly tuned management systems will drive of user-specific information with editorial, important to seek the licensing teams to be more productive. combining lead searches with contact lists to new opportunities They step over the path. create a more dynamic environment. These Other companies believe that licensing innovations are the only way in which such in uncharted waters. a new product is easy, and is a matter conglomerates are going to survive against Everyone needs of keeping an eye on the industry press, attending as many conferences as possible, the onslaught of free web products. There are, however, a few sites that differentiation and working the rolodex and networking. They proactively seek out new companies innovation. do not reach the path. that have products to license and need To find new partners or products and help getting more visibility. These include to avoid license auctions, it is important to pharmadeals.com, pharmalicensing.com, seek new opportunities in uncharted waters. pharmaprojects.com, sourcegenerics.com These ideas are not just relevant for big and farmavita.net. On some of these sites pharma or generic giants; everyone needs it is possible to save searches and have new differentiation and innovation. There are companies that match criteria sent via email existing opportunities and future ventures automatically, so you need only visit once to that could unearth the new opportunities, get a stream of potential leads. The internet including online databases/portals, is now the first place companies research virtual partnering forums, internet speed potential new marketing partners. networking, niche partnering events and collaboration platforms. Virtual partnering forums Although there are a few events in the Online databases/portals calendar already, this is going to be an Companies that offer deal data are nothing area of massive growth in coming years. revolutionary; the advent of online news feed Modelled on real-world conference centres, aggregation means that press statements are each has exhibition booths with multimedia distributed from every angle instantaneously. displays and live chat (with video and voice if While such news sites can provide a lead list desired), keynote speaker presentations and of active licensing companies, the fact they networking lounges. are announcing a deal normally means it’s Improving broadband connections, >> www.plg-uk.com Issue 12 | June 2010 21
  • 4. To discover unknown companies and exciting products, one needs to get out of the zoo and into the jungle. Such exotic terrain requires a specialist tour guide. >> streaming media and browser-based 20 minutes over 2 hours) and not have to applications are all making virtual reality even leave the office? a much richer and more stimulating Webcams, Skype and simple web environment. interfaces will soon enable licensing teams, Reduced budgets, increased focus on brokers and industry associations to host well carbon footprints and greater time pressures researched events that have a better than are all factors which count against the average return on time invested. traditional big shows and live partnering events. This pressure is increased when Niche partnering events considering emerging markets with excellent Bigger isn’t always better. The giant IT infrastructure and executives that are a partnering events like Bio, while enabling little less inclined to travel or blow budgets on thousands to meet under one roof, is focused only a few trips a year. on volume of attendees and meetings. To Events already in the calendar discover unknown companies and exciting include bioconferencelive.com, products, one needs to get out of the zoo pharmapartneringlive2010.com, and into the jungle. Such exotic terrain cardiocarelive.com and informex.com/virtual. requires a specialist tour guide; one with Some of the larger pharma companies local knowledge and a connection with the now have their own partnering web environment. presence; although not well promoted, they There are already a number of key events provide a 24/7 opportunity for engagement on the calendar in high-growth markets, and information sharing with potential including innchinc.com/wpcs2010, cphi-sa. partners. Expect to see many more of these com, eilat-aeds.com and kenes.com/ipa. virtual meeting spaces as a cost-effective way We can expect to see an increased focus on to attract interest from every corner of the therapy areas and research and development Expect to see industry. technologies. many more virtual Internet speed networking Collaboration platforms meeting spaces as a Sometimes introductory meetings can take much longer than necessary or desired and The future of licensing deals, ie one company acquiring the rights to another’s intellectual cost-effective way to can be especially unproductive if they are part property, is a model that will morph as attract interest from of the mandatory requirements of partner technology and business structures develop. every corner of the events. What better than to have multiple In other industries where innovation, consumer (patient) alignment and long-term industry. meetings in a short space of time (say every value is a high priority, companies are joining 22 Business Development & Licensing Journal www.plg-uk.com
  • 5. together in collaboration like never before. networks may not be an effective channel Given the global Web 2.0 is about integration, open source and user content creation. Business 2.0 (or into the new opportunities. To connect with the developers of tomorrow is going to spread of future more like 200.0) will mimic this trend, as require a more high-tech approach. intellectual workers, corporations seek to compete with the next The internet is making the world and personal contacts Facebook/Spotify/Apple of their space and every industry smaller; companies from start-ups discover game-changing ways to every corner of the globe should be seeking and networks may work together, disrupting the establishment. ways to do business with each other before not be an effective How will the pharma industry look in 10 years’ time? How will that affect licensing? someone else does. If, as forecast, the BRIC countries are going channel into the new Pharma is founded on research and to dominate the future economy, are you opportunities. development (more development in already connected in those markets? If not, generics) and finding better ways to bring why not? If, as forecast, technology is going more products to market. One way that to change the face of all industries, including the corporate model could be challenged pharma, are you investigating how you can is through the creation of loose networks get ahead of the game? If not, why not? of specialist teams and individuals for Tomorrow’s deals are not going to wait for specific projects, or to harness a unique joint you. capability. In the future, the products to license are With such experts having access to not going to be found in the same places powerful technology infrastructure and as yesterday or today. The individuals and a willingness to achieve more through countries that will create the products of collaboration, licensing deals may be done tomorrow will be better integrated with with individuals or specific business vehicles. technology and more accessible to those who embrace the same. The future There are already more innovative ways The future integration and collaboration of to engage with new partners with new development bodies could make deal making products; it just takes a little step out into the a lot more complex. Such open platforms unknown, to depart from the old school and could also mean that options and sponsorship adopt some new tools. or other commercial tools could tie up the best minds before the products reach the licensing space. Given the global spread of future intellectual workers, personal contacts and www.plg-uk.com Issue 12 | June 2010 23